EMD Emyria Expands to NSW - Matilda Partnership

Emyria (ASX:EMD) is expanding into NSW with a new psychedelic-assisted therapy clinic at Matilda Nepean Private Hospital in Western Sydney, marking a major milestone in Australia's emerging mental health treatment sector.

This partnership with Matilda Healthcare brings Emyria's national footprint to 5 clinic locations across 4 states, adding 4 treatment beds for a total capacity of 18 beds nationwide. The Western Sydney location will serve a catchment area of over 2.5 million people when it opens in Q3 2026.

In this video, we break down:
✅ Emyria's strategic expansion into Australia's most populous state
✅ How the company doubled its network of Authorised Prescriber psychiatrists from 6 to 12
✅ The significance of the Empax Global Partnership Program for clinical trials
✅ What this means for the future of psychedelic-assisted therapy in Australia
✅ Market positioning with a $40M market cap

The expansion strengthens Emyria's Empax Global Partnership Program, positioning the company to offer clinical trial infrastructure and real-world evidence generation for international drug development sponsors.

With 8 additional psychiatrists undergoing training in June 2025, Emyria is building critical capacity in a sector that's gaining regulatory acceptance and clinical validation worldwide.

🔔 Subscribe for more ASX biotech and healthcare news
👍 Like this video if you're following the psychedelic therapy sector

#EmyriaASX #PsychedelicTherapy #ASXBiotech #MentalHealthInnovation #NSWHealthcare #MatildaHealthcare #EmpaxProgram #ASXNews #AustralianBiotech

Видео EMD Emyria Expands to NSW - Matilda Partnership канала StockWire X | ASX News